FDA Announces Recall of Compounded GLP-1 Injections Over Sterility Concerns

Apothecary Pharma is recalling 23 vials of compounded GLP-1 injections, including tirzepatide, due to a 'lack of assurance of sterility.' The U.S. Food and Drug Administration (FDA) elevated this to a Class II recall, indicating that use of the affected products may cause temporary or medically reversible adverse health consequences. The pharmacy had previously received an FDA warning letter for serious deficiencies in its practices.